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Abstract
Background: It is believed that the endotoxin lipopolysaccharide (LPS) is implicated in the metabolic perturbations
associated with both sepsis and obesity (metabolic endotoxemia). Here we examined the role of inducible nitric oxide
synthase (iNOS) in skeletal muscle insulin resistance using LPS challenge in rats and mice as in vivo models of endotoxemia.
Methodology/Principal Findings: Pharmacological (aminoguanidine) and genetic strategies (iNOS
2/2 mice) were used to
counter iNOS induction in vivo. In vitro studies using peroxynitrite (ONOO
2) or inhibitors of the iNOS pathway, 1400 W and
EGCG were conducted in L6 myocytes to determine the mechanism by which iNOS mediates LPS-dependent insulin
resistance. In vivo, both pharmacological and genetic invalidation of iNOS prevented LPS-induced muscle insulin resistance.
Inhibition of iNOS also prevented insulin resistance in myocytes exposed to cytokine/LPS while exposure of myocytes to
ONOO
2 fully reproduced the inhibitory effect of cytokine/LPS on both insulin-stimulated glucose uptake and PI3K activity.
Importantly, LPS treatment in vivo and iNOS induction and ONOO
2 treatment in vitro promoted tyrosine nitration of IRS-1
and reduced insulin-dependent tyrosine phosphorylation.
Conclusions/Significance: Our work demonstrates that iNOS-mediated tyrosine nitration of IRS-1 is a key mechanism of
skeletal muscle insulin resistance in endotoxemia, and presents nitrosative modification of insulin signaling proteins as a
novel therapeutic target for combating muscle insulin resistance in inflammatory settings.
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Introduction
Nitrosative modification of target molecules is becoming
increasingly recognized as an important intracellular signaling
mechanism. Rapidly reversible and regulated in large part by local
nitric oxide (NO) status, this class of post-translational modification
appears to be a selective process that targets specific cysteine and
tyrosine residues to activate or restrict cellular events [1,2,3].
Unsurprisingly, accumulating evidence suggests that these modifi-
cations carry important implications for whole body physiology and
are highly relevant to the pathophysiology of a growing number of
disease states, particularly those with an inflammatory base.
Cellular NO availability is regulated by the activities of three
nitric oxide synthase (NOS) isozymes. Two constitutively
expressed Ca
2+-dependent enzymes, the endothelial form (eNOS)
and the neuronal form (nNOS), and a transcriptionally regulated
inducible form (iNOS)[4,5]. In contrast to the two constitutive
members of the NOS family, iNOS, once induced, is capable of
generating large amounts of NO for a prolonged period of time
[6,7,8]. In fact, iNOS may produce up to one thousand times
more NO than both eNOS and nNOS combined. As a result of
this superior capacity, factors that regulate iNOS induction may
exert a critical influence on cellular physiology via widespread
induction or reduction of nitrosative modifications.
We first proposed that insulin resistance (IR) is linked to iNOS
induction in skeletal muscle and other insulin target cells during
systemic inflammation. We showed that administration of the
endotoxin lipopolysaccharide (LPS), a model of acute systemic
inflammation, induces iNOS in muscle, liver, and adipose tissue
[9,10]. Cytokine-mediated iNOS expression in muscle elevates
basal glucose uptake but causes marked IR [9,10,11] and both can
be abrogated by iNOS inhibition in muscle cells in vitro [11]. We
further provided genetic evidence that iNOS induction in skeletal
muscle modulates whole-body glucose metabolism and mediates
skeletal muscle IR in obese high-fat fed mice [12]. This finding was
in line with well documented evidence showing that obesity is a
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sion of multiple inflammatory cytokines known to induce iNOS
such as TNF-a, interferon-c, IL-6, and IL-1b [13]. However, it is
still unclear whether iNOS induction in acute models of systemic
inflammation also underlies skeletal muscle IR. One study showed
that mice lacking iNOS were protected from LPS-mediated IR as
determined by an insulin tolerance test but skeletal muscle insulin
sensitivity was not determined in this study [14]. Furthermore,
despite numerous reports of elevated iNOS expression in both
acute and chronic inflammatory settings the underlying molecular
mechanism by which iNOS mediates skeletal muscle IR remains
ill-defined. This question is also relevant to obesity-linked
inflammation since the finding that LPS levels are increased in
obese insulin resistant mice as a result of perturbations of the gut
microbiota that cause metabolic endotoxemia [15].
Targeted protein S-nitrosylation is one form of nitrosative
modification that has been suggested to contribute to the insulin
desensitizing actions of iNOS [14,16,17]. The presence of
nitrosothiol adducts on cysteine residues in glycosylated hemoglo-
bin is elevated in patients with type 2 diabetes and it appears that
in skeletal muscle of obese diabetic mice this form of nitrosative
modification may be directly targeted towards key enzymes of the
insulin signaling cascade. Indeed, increased S-nitrosylation of
insulin signaling proteins has been reported in both obese and
LPS-treated animals [14,16,17]. Interestingly, the presence of
reactive oxygen species (ROS) was shown to enhance the impact of
the NO donor SNAP on Akt activity [18]. Although this was
apparently associated with enhanced S-nitrosylation of Akt, the
potential for other complementary nitroxyradical mediated
nitrosative modification such as tyrosine nitration of Akt was not
determined in this study.
Indeed, NO is also known to readily react with superoxide
(O2
2) to form peroxynitrite (ONOO
2) [19]. This powerful
oxidant has been reported to modulate cellular functions through
the nitration of tyrosine residues. The biological reactivity of
ONOO
2 for tyrosine nitration actually depends on radical
intermediates arising from the interaction of ONOO
2 with CO2
[20,21]. The CO3
2 radicals produced in this reaction generate
secondary radicals on tyrosine residues with which the less reactive
NO2 couples to form the nitrated product [21]. It is noteworthy
that nitrated proteins have been detected in at least 50 human
disorders such as Alzheimer disease, rheumatoid arthritis,
glaucoma, asthma and inflammatory bowel disease [22], and
multiple groups have reported that protein tyrosine nitration is
elevated in plasma and tissues of type 2 diabetics [23,24].
Moreover, it has been shown that nitration of tyrosine residues
decreases their subsequent phosphorylation capacity [25]. We
have recently reported that lipid infusion in mice causes hepatic IR
by promoting iNOS induction and tyrosine nitration of insulin
signaling proteins in liver [26]. Mice lacking iNOS were protected
from this effect indicating that the iNOS/NO/ONOO
2 pathway
is a key mediator of hepatic IR upon lipid challenge. Whether
tyrosine nitration also mediates iNOS-linked IR in skeletal muscle
remains to be investigated. The aim of this study was therefore to
determine the role of iNOS and ONOO
2 in skeletal muscle IR
using in vivo and in vitro models of endotoxemia, where iNOS
induction is known to exert a pathological role.
Results
Inhibition of iNOS prevents IR in skeletal muscle of LPS-
treated rats
To study the role of iNOS in muscle IR, we treated rats with
LPS in the presence or absence of the iNOS inhibitor
aminoguanidine. LPS was found to induce iNOS as reflected by
iNOS protein expression and plasma NO production (Figure 1A
and B). As expected, pretreatment with aminoguanidine (100 or
150 mg/kg) blocked NO production and iNOS protein expression
in a dose dependent manner (Figure 1A and B). However, the two
constitutive NOS enzymes, eNOS and nNOS, were not affected
by aminoguanidine treatment.
We next investigated the influence of iNOS induction on insulin
sensitivity ex vivo by measuring glucose uptake in isolated soleus
muscle from these rats. Insulin-stimulated glucose uptake was
reduced in LPS-treated animals compared to the control group
(Figure1C). Aminoguanidine treatment restored insulin-stimulated
glucose uptake in LPS treated animals in a dose-dependent
manner such that the lower dose of aminoguanidine partially
improved insulin sensitivity while the higher dose fully restored
muscle insulin action (Figure 1C).
We had previously reported that iNOS induction causes IR at
least in part through inhibition of IRS-1 associated PI 3-kinase
[12,27]. Therefore, we determined whether the activity of this
enzyme was altered in LPS-treated rats. LPS treatment decreased
the ability of insulin to stimulate PI 3-kinase activity while iNOS
inhibition with aminoguanidine fully restored insulin’s action on
PI 3-kinase (Figure 1D).
Targeted iNOS disruption in mice protects against LPS-
induced IR
Since aminoguanidine can also inhibit the formation of
advanced glycation endproducts [28] we next used a genetic
model of iNOS disruption to further demonstrate the role of iNOS
in LPS-induced IR. As expected, LPS challenge induced iNOS
and subsequent NO production was observed in wild-type
(iNOS
+/+) mice but was fully abrogated in iNOS
2/2 littermates
(Figures 2A and B). As with aminoguanidine inhibition, genetic
deletion of iNOS was associated with protection from LPS-
induced IR. Indeed, as expected iNOS
+/+ LPS treated mice
displayed elevated basal glycemia (Figure 2C) and a reduced
glucose infusion rate compared to saline treated controls
(Figure 2D and E) during the hyperinsulinemic-euglycemic clamp
(HIEC). This was not the case in LPS-treated iNOS
2/2 mice
whose basal glycemia and glucose infusion rate during the HIEC
was similar to that of saline treated mice. In fact, saline treated
iNOS
2/2 mice did not vary from their iNOS
+/+ counterparts for
any of the parameters measured during the HIEC. Importantly,
the LPS-mediated skeletal muscle IR revealed by reduced
peripheral glucose uptake in iNOS
+/+ mice was completed
prevented in iNOS
2/2 mice (Figure 2F). This finding was further
supported by ex vivo glucose transport experiments in which
insulin-mediated 2-deoxyglucose uptake was impaired in LPS-
treated iNOS
+/+ animals but normalized in the soleus of LPS-
treated iNOS
2/2 mice compared to their saline treated controls
(Figure 2G). Moreover, LPS-mediated inhibition of insulin-
stimulated phosphatidylinositol 3-kinase (PI3K) activity in skeletal
muscle was also significantly improved by iNOS deletion
(Figure 2H).
To gain further understanding of the molecular mechanisms
underlying iNOS-induced IR we next examined IRS-1 tyrosine
nitration and phosphorylation in skeletal muscle from saline and
LPS-treated iNOS
+/+ and iNOS
2/2 mice that had undergone the
HIEC procedure. We found a marked increase in tyrosine
nitration of IRS-1 in the muscle of LPS-treated iNOS
+/+ mice
compared to their saline treated counterparts (Figure 3A).
Remarkably tyrosine nitration of IRS-1 was completely abrogated
in LPS-treated iNOS
2/2 mice. Importantly the increase in
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decrease in tyrosine phosphorylation in vivo (Figure 3B).
iNOS inhibits insulin-stimulated glucose uptake via the
production of ONOO
2
We next explored whether iNOS-mediated IR and IRS-1
tyrosine nitration could be recapitulated in vitro in muscle cells
exposed to endotoxin and inflammatory cytokines. The cellular
model also allows us to test whether ONOO
2 may be involved in
iNOS-linked tyrosine nitration of IRS-1 and inhibition of insulin
signaling to PI3K. Exposure of muscle cells to cytokine/LPS for
24 hrs markedly induced NO production as detected by the
accumulation of nitrite in the culture medium and this was
completely inhibited by co-incubation with the iNOS inhibitor
1400 W (ctr: 0.03 +/2 0.07 mM, cyto/LPS: 9.18 +/2 0.62 mM,
cyto/LPS+1400 W: not detected). In agreement with our previous
observations that iNOS induction increases GLUT1 expression in
L6 myocytes [11], cytokine/LPS treatment increased basal glucose
transport (Figure 4A). This elevated basal glucose uptake was not
observed in rat or mouse muscles likely because of the shorter time
of LPS exposure (6 hrs) as compared to the 24 hrs treatment of
muscle cells with the cytokine/LPS mixture. Importantly, co-
incubation with the iNOS inhibitor 1400 W blunted the cytokine/
LPS-mediated increase in basal glucose uptake. Cytokine/LPS
exposure also significantly decreased insulin-stimulated glucose
transport (Figure 4B) and this impairment was also reversed by
iNOS inhibition. These results clearly support the in vivo findings
showing a role for iNOS in LPS–induced IR.
We also studied the effect of epigallocathechin gallate (EGCG),
an alternative inhibitor of the iNOS pathway, in cytokine/LPS
Figure 1. Effect of aminoguanidine on iNOS induced insulin resistance in muscle in vivo. Rats were injected i.p with LPS 20 mg/kg with or
without aminoguanidine (100 or 150 mg/kg) and sacrified 6 hours later. A) Nitrite accumulation in plasma was measured by fluorometry. Data are
mean 6SEM; *P,0.05 vs LPS control. B) NOS enzyme protein expression was measured by western blot in soleus muscle. C) Effect of LPS with or
without aminoguanidine was measured on basal or insulin stimulated glucose transport in strips of soleus muscle. Data are mean 6SEM; *P,0.05 vs
control, {P,0.05 vs LPS. D) IRS-1 associated PI 3-kinase activity was measured in muscle of LPS +/2 aminoguanidine (150 mg/kg) treated animals.
Insulin (3,8 U/kg i.v) was injected 4 minutes prior to sacrifice. Data are mean 6SEM; *P,0.05 vs insulin control, {P,0.05 vs LPS.
doi:10.1371/journal.pone.0015912.g001
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+/+(WT) or iNOS
2/2 (KO)
mice were treated with saline (SAL) or LPS A) nitrite accumulation in plasma was measured by fluorometry. Data are mean 6SEM; **P,0.01 vs saline
control. B) representative blot of NOS Protein expression in skeletal muscle of type iNOS
+/+ or iNOS
2/2 mice treated with saline (SAL) or LPS. C) Blood
glucose measured during the HIEC. Data are mean 6SEM; *P,0.05 vs iNOS
+/+(WT) saline control. D) Glucose infusion rate during the HIEC. Data are
mean 6SEM; *P,0.05 vs iNOS
+/+(WT) saline control. E) Mean glucose infusion rate during the last 60 minutes of the HIEC. Data are mean 6SEM;
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mediated-iNOS inhibition, EGCG treatment also blunted the
increase of basal glucose transport and reversed the deleterious
effect of iNOS induction on insulin-stimulated glucose uptake
(Figures 4C and 4D). Next, we treated cells directly with authentic
ONOO
2. As observed for cytokine/LPS mediated-iNOS induc-
tion, ONOO
2 treatment stimulated basal glucose transport while
inhibiting insulin-stimulated glucose uptake (Figures 4E and 4F).
These data imply that the reactive nitrogen derivative ONOO
2
may be responsible for the deleterious effects of iNOS on insulin-
stimulated glucose transport.
ONOO
2 reproduces the inhibitory effect of iNOS
induction on PI3K activity
Reminiscent of the in vivo study, we observed an association
between the cytokine/LPS-induced defect in insulin-stimulated
glucose transport and impaired insulin signal transduction through
IRS-1/PI3K in the cellular model. Cytokine/LPS treatment
caused ,50% reduction in insulin-stimulated IRS-1-associated
PI3K activity as compared to control cells (Figures 5A and 5B).
Importantly, both 1400 W and EGCG restored insulin-stimulated
PI3K activity in cytokine/LPS treated cells, while exposure to
authentic ONOO
2 mimicked the cytokine/LPS treatment and
blunted the ability of insulin to induce IRS-1 associated PI3K
activity (Figure 5C). Neither 1400 W nor EGCG alone modulated
PI3K activity (data not shown) and no effect of cytokine/LPS or
ONOO
2 was observed on basal PI3K activity. These results
support a role for ONOO
2 in the iNOS-induced defect in insulin-
stimulated PI3K activity in skeletal muscle cells.
ONOO
2 causes tyrosine nitration of IRS-1
Since free ONOO
2 interacts with proteins to form nitrotyrosine
adducts, we screened for the presence of this modification on IRS-
1, a critical element for insulin action that was determined to be a
site of defective insulin signaling in both the animal and cellular
models studied here. To evaluate specifically the nitration of IRS-1
we first immunoprecipitated proteins containing nitrotyrosine
adducts using the antinitrotyrosine antibody and probed for IRS-1
in lysates from L6 muscle cells treated with or without cytokine/
LPS in the absence or presence of 1400 W. In line with our
findings concerning insulin signaling to PI3K, cytokine/LPS
treatment was found to promote tyrosine nitration of IRS-1 and
this was blunted by treatment with the iNOS inhibitor 1400 W
(Figure 6A). These results were confirmed by performing the
reverse experiment where IRS-1 was first immunoprecipitated,
followed by western blotting with the anti-nitrotyrosine antibody.
Importantly, increasing doses of ONOO
2 were also found to
promote tyrosine nitration of IRS-1(Figure 6B).
We next determined whether nitration of IRS-1 on tyrosine
residues could decrease its capacity for insulin-stimulated tyrosine
phosphorylation. To do so we measured IRS-1 tyrosine phos-
phorylation in cells treated with insulin in the absence or presence
of ONOO
2. We found that ONOO
2 treatment significantly
decreased insulin-induced tyrosine phosphorylation on IRS-1
(Figure 6C). Taken together these data indicate that ONOO
2
mediated tyrosine nitration of IRS-1 largely accounts for iNOS-
induced IR in skeletal muscle cells.
Discussion
The advent of metabolic endotoxemia as an important
contributor to obesity-linked inflammation and IR has renewed
scientific interest in defining the mechanisms underlying LPS-
induced perturbations in glucose metabolism [15]. Herein, using
both in vivo and in vitro models of endotoxemia we delineated the
important role that iNOS-dependent tyrosine nitration of the
proximal insulin signaling intermediate, IRS-1, plays in endotox-
emia-induced skeletal muscle IR. Our data not only establish a key
role for iNOS but also suggest a role for the reactive nitrogen
derivative ONOO
2 in the metabolic consequences of iNOS
Figure 3. Effect of LPS treatment on tyrosine nitration and
phosphoylation of IRS-1 in mouse skeletal muscle. A) Skeletal
muscle lysates from wild type iNOS
+/+(WT) or iNOS
2/2 (KO) mice treated
with saline (SAL) or LPS were immunoprecipitated with anti-IRS-1
antibody and then immunoblotted with anti-nitrotyrosine antibody B)
lysates were also immunoprecipitated with anti-phosphotyrosine
antibody (4G10) and then immunoblotted using the IRS-1 antibody.
The quantification shown below the representative gels was normalized
for total IRS-1. Data are mean 6SEM; *P,0.05 vs iNOS
+/+ saline control




+/+(WT) saline control, {P,0.05 vs iNOS
+/+(WT) LPS. F) Basal and Clamp peripheral glucose uptake. Data are mean 6SEM; *P,0.05 vs
iNOS
+/+(WT) saline control, {P,0.05 vs iNOS
+/+(WT) LPS. G) Basal and insulin stimulated 2-Deoxy-glucose uptake in isolated soleus of iNOS
+/+ or
iNOS
2/2 mice treated with saline (SAL) or LPS. Data are mean 6SEM; **P,0.01 vs iNOS
+/+(WT) saline insulin control. H) Insulin induced IRS-1-
associated PI 3-kinase activity. Data are mean 6SEM; *P,0.05 vs iNOS
+/+ control (CTL), {P,0.05 vs iNOS
+/+ LPS.
doi:10.1371/journal.pone.0015912.g002
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2 and iNOS induction on glucose transport in L6 muscle cells. The effect of cyto/LPS on basal (panel A) and
insulin stimulated (panel B) glucose uptake was measured in L6 muscle cells treated with TNF-a (10 ng/ml), IFN-c (200 units/ml) and LPS (10 mg/ml)
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ONOO
2 was able to fully reproduce the effect of cytokine/LPS-
mediated iNOS induction on glucose transport, insulin signaling to
PI3K, IRS-1 tyrosine nitration and phosphorylation. Importantly,
the use of iNOS
2/2 mice allowed us to provide genetic evidence
for iNOS-dependent IRS-1 tyrosine nitration in skeletal muscle in
vivo.
Until now our understanding of the molecular mechanisms by
which iNOS mediates IR in skeletal muscle was limited to NO
mediated S-nitrosylation [18]. In the present work we show for the
first time that the radical NO oxidation product ONOO
2 also
contributes to iNOS-mediated insulin signaling defects in skeletal
muscle via tyrosine nitration of IRS-1. This post-translational
modification appears to impede insulin signal transduction by
blocking tyrosine phosphorylation of IRS-1 and thereby limiting
its interaction with PI3K.
Our report of a negative role for elevated tyrosine nitration in
skeletal muscle cells exposed to cytokines and LPS or authentic
ONOO
2 is in line with observations made in other cell types. To
date ONOO
2 mediated tyrosine nitration has been shown to
negatively modulate the function of several enzymes such as
glutamine synthase, prostacyclin synthase, cytochrome P450,
tyrosine hydrolase and sarcoplasmic reticulum Ca-ATPase
[30,31,32,33,34]. Furthermore, tyrosine nitration has also been
associated with impaired PI 3-kinase activity in endothelial cells,
macrophages and 3T3-L1 adipocytes exposed to authentic
ONOO
2 in vitro [30,31,32,33,34].
Although studies in cells had previously shown the potential for
authentic ONOO
2 to impair insulin stimulated PI 3-kinase
activity in vitro it was not yet known whether this was a
physiologically relevant occurrence in major insulin target tissues.
However, we recently reported that iNOS dependent tyrosine
nitration of IRS-1 and IRS-2 underlies lipid-induced IR in liver
[26]. In this study, we found that acute 6 h lipid infusion like LPS
treatment promotes iNOS induction in liver and this is
accompanied by IR and tyrosine nitration of insulin signaling
intermediates that is completely prevented in liver of iNOS
2/2
mice. In the present paper we now provide evidence that iNOS-
linked IRS-1 tyrosine nitration also underlies skeletal muscle IR in
the acute inflammatory setting of endotoxemia. Furthermore this
in vivo finding was recapitulated in L6 myocytes where we show
that chronic cytokine/LPS treatment or acute exposure to
authentic ONOO
2 increased tyrosine nitration of IRS-1, resulting
in decreased IRS-1 tyrosine phosphorylation and impaired
activation of PI3K, leading to defective insulin stimulation of
glucose transport. These effects were reversed by pre-treatments
with inhibitors of the iNOS pathways (1400 W and EGCG).
Moreover, both cytokine/LPS and ONOO
2 treatments were
found to promote tyrosine nitration of IRS-1. Again, these defects
were corrected by iNOS inhibition with 1400 W, further
supporting the concept that IRS-1 tyrosine nitration by ONOO
2
underlies iNOS-induced muscle IR. Importantly, as with most
other post-translational modifications, tyrosine nitration is a
selective process and not all tyrosine residues present in proteins
are nitrated. To date no specific consensus sequence or motif has
been identified for protein tyrosine nitration. However, it is known
that the presence of one or more acidic residues and a relative
paucity of cysteine, methionine and basic amino acids are required
for tyrosine nitration to occur [22]. After searching the sequence of
IRS-1 we have identified one tyrosine residue that responds to
these criteria, the tyrosine at position 895 in rat or 896 in humans.
Further experiments will be needed to determine whether this key
tyrosine is the target of ONOO
2 nitration in skeletal muscle.
One report showed that increasing ONOO
2 with a NO/O2-
donor (SIN-1) inhibited insulin-stimulated glucose transport and
IRS-1-associated PI3K activity in 3T3-L1 adipocytes [35]. This
was associated with increased nitration of tyrosine residues within
IRS-1. However, the physiological relevance of such data is not
clear as very high concentrations of SIN-1 were used in this paper.
Moreover, we found no evidence for iNOS-linked IR in cytokine-
exposed adipocytes or adipose tissue of obese mice [36,37]. Since
iNOS derived ONOO
2 formation is dependent upon O2
2
availability, the discrepancy regarding the role of iNOS as a
direct mediator of IR in muscle and fat cells could potentially be
the result of contrasting tissue reactive oxygen species profiles.
Indeed, protein carbonyl levels, a marker of cumulative oxidative
stress, were recently reported to be increased in liver but not in
adipose tissue of mice fed a high fat diet for 6 weeks [38]. If a
similar difference in oxyradical accumulation exists between
muscle and adipose tissue, it could perhaps explain the differential
impact of iNOS induction on insulin signal transduction in these
two tissues. On this note it is important to mention that skeletal
muscle oxygen consumption in the resting state is approximately
10 fold greater than that of white adipose tissue, potentially leading
to greater mitochondrial O2
2 generation in this tissue [39].
Alternatively, in the presence of equivocal O2
2 generation,
differences in O2
2 scavenging among the two tissues could also
contribute to a discrepancy in ONOO
2 formation. Future studies
should thus examine the influence that factors modulating O2
2
generation and scavenging have on the impact of iNOS in insulin
target tissues.
In conclusion, the present results obtained from rats, mice and
L6 myocytes in culture strongly suggest that ONOO
2 is a key
mediator of skeletal muscle IR following iNOS induction. This
oxidant derivative inhibits insulin action via tyrosine nitration of
IRS-1 which impedes IRS-1 tyrosine phosphorylation and its
associated PI3K activity. These findings provide new insights into
the mechanism linking iNOS to skeletal muscle IR in inflamma-
tory settings. Our work also presents nitrosative modification of
insulin signaling proteins as a novel therapeutic target for
improving muscle IR following LPS exposure during endotoxin
shock or obesity-linked metabolic endotoxemia.
Materials and Methods
Ethics statement
This study was approved by the Animal Care and Handling
Committee of Laval University (authorization number 08-032 and
00-041).
Materials
Interferon-c and TNF-a were purchased from Research
Diagnostics Inc., (Flanders, NJ), and RD systems (Minneapolis,
MN), respectively. 1400 W and polyclonal nitrotyrosine antibody
for 24 hours, +/2 1400 W expressed as fold change or percent insulin action respectively. Data are mean 6SEM; *P,0.05 vs control, #P,0.05 vs
cyto/LPS. (C) The effect of EGCG (10 mM) on basal glucose transport in the presence of cytokines/LPS. Data are mean 6SEM; *P,0.05 vs control. (D)
The effect of EGCG(10 mM) on insulin stimulated glucose transport in the presence of cytokines/LPS. Data are mean 6SEM; *P,0.05 vs control. (E)
Basal glucose transport in the presence of increasing concentrations of ONOO
2. Data are mean 6SEM; *P,0.05 vs control (ctr). F) Insulin-stimulated
glucose transport in the presence of increasing concentrations of ONOO
2. Data are mean 6SEM; *P,0.05 vs control.
doi:10.1371/journal.pone.0015912.g004
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solutions and supplements were purchased from Life Technolo-
gies, Inc. except for fetal bovine serum, which was purchased from
Wisent (St-Bruno, QC, Canada). Reagents for SDS-polyacryl-
amide gel electrophoresis and immunoblotting were from Bio-
Rad. ECL and [2-
3H]Deoxyglucose were from PerkinElmer Life
Sciences. [c-
32P]ATP, protein A- and G-Sepharose, anti-mouse or
anti-rabbit immunoglobulin G conjugated to horseradish perox-
idase were purchased from Amersham Pharmacia Biotech (Baie
d’Urfe ´, QC, Canada). Polyclonal antibodies against IRS-1 (raised
against 20 C-terminal amino acids (C-20)), were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). The antibody IRS-1
for the western blot was from Cell Signaling (Beverly, MA).
Polyclonal iNOS antibody was purchased from Upstate Biotech-
nology and eNOS and nNOS antibodies were from transduction
(San Jose, CA). Monoclonal antibody against phosphotyrosine was
obtained from Upstate Biotechnology (Lake Placid, NY). Human
insulin was obtained from Eli Lilly (Toronto, ON, Canada). L-a -
phosphatidylinositol was from Avanti Polar Lipids (Alabaster, AL).
Oxalate-treated TLC silica gel H plates were obtained from
Analtech (Newark, DE). All other chemicals were from Sigma
(St.Louis, MO).
Cell culture
L6 myoblasts were grown in a-MEM (10% FBS) containing 1%
antibiotic/antimycotic (100 000 units/ml penicillin, 100 mg/ml
streptomycin, 0.25 mg/ml amphotericin) and differentiated into
myotubes in a-MEM (2% FBS) as previously described [11]. iNOS
was induced by exposing cells to TNF-a (10 ng/ml), IFN-c
(200 U/ml) and LPS (10 mg/ml) for 24 hours. The incubation
medium was kept to assess nitrite accumulation determined
spectrophotometrically as described previously [11].
Animals
Male Sprague-Dawley rats (200–250 g) purchased from Charles
River (Montre ´al, Canada) were used in the aminoguanidine
studies. Rats were pre-treated with a single intraperitoneal
injection of aminoguanidine or saline (vehicle) 30 min prior to
LPS (20 mg/kg, BW) or saline treatment. Animals were sacrificed
6 h later, and muscles tissues were removed and stored at 280uC
until further processing. iNOS2/2 mice (C57BL/6J crossbred),
originally provided by C. Nathan and J.S. Mudgett (Cornell
University) have been described previously [12]. The mice were
kept under specific pathogen-free conditions at the Animal Facility
of Laval University hospital research center and were given free
access to a standard low-fat diet (Purina Rodent Chow, Madison,
Wisconsin). For ex-vivo skeletal muscle glucose uptake experi-
ments mice were sacrificed 6 h after LPS treatment (20 mg/kg).
Hyperinsulinemic-euglycemic clamp procedure.
Wild-type and iNOS2/2 were randomly assigned to either
saline or LPS (20 mg/kg) treatment groups. Five days prior to the
experiment, mice were anesthetized and catheters inserted into the
left common carotid artery and the right jugular vein for blood
sampling and infusions, respectively. The free catheter ends were
tunneled under the skin, externalized at the neck, and sealed. Mice
were fasted for 5 h before the clamp procedure. The intravenous
infusion catheters were connected to a swivel 1 h prior to the
infusion, and the mice were unrestrained and not handled
thereafter to minimize stress. Two and a half hours after LPS
administration (t=150 min), the hyperinsulinemic-euglycemic
clamp (HIEC) was initiated according to previously described
methodology [26,40]. At the end of the clamp, mice were
anesthetized, cardiac punctures were performed and hindlimb
muscles were excised, freeze-clamped, and stored at 280uC until
further analyses. Peripheral glucose uptake was determined using
Mari’s non–steady-state equations [41].
Figure 5. Effect of iNOS and ONOO
2 on IRS-1-associated PI 3-kinase activity in L6 myocytes. PI 3-kinase was measured in anti-IRS-1
immunoprecipitates of L6 cells treated with A) cyto/LPS with TNF-a (10 ng/ml), IFN-c (200 units/ml) and LPS (10 mg/ml) for 24 hours, +/2 iNOS
inhibitor 1400 W (0,1 mM), B) +/2 EGCG (10 mM) or C) in cells directly treated for 1 hour with ONOO
2 . Quantification of
32P incorporated into PI 3-
phosphate (PI 3P) was expressed relative to insulin control value. A representative autoradiograph is shown at the top of the figure. Data are mean
6SEM; *P,0.05 vs the indicated group.
doi:10.1371/journal.pone.0015912.g005
Figure 6. Effect of ONOO
2 and iNOS induction on IRS-1
tyrosine nitration and phosphorylation. A) Protein lysates from
cells treated with and cytokines +/2 the iNOS inhibitor 1400 W
(0.1 mM) were immunoprecipitated with anti-nitrotyrosine antibody
and then immunoblotted with anti-IRS-1 antibody or immunoprecip-
itated with anti-IRS-1 antibody and then immunoblotted with anti-
nitrotyrosine antibody. B) Protein lysates from cells treated with
increasing doses of ONOO
2 were immunoprecipitated with anti-
nitrotyrosine antibody and then immunoblotted with anti-IRS-1
antibody or immunoprecipitated with anti-IRS-1 antibody and then
immunoblotted with anti-nitrotyrosine antibody. C) L6 cells were serum
deprived for 4 hours and then treated with or without ONOO
2 for
1 hour. Cells were then stimulated with 100 nM insulin for the last 5
minutes of the treatment. Cell lysates were immunoprecipitated with
anti-phosphotyrosine antibody (4G10) and then immunoblotted using
the IRS-1 antibody. Gels are representative of two independent
experiments.
doi:10.1371/journal.pone.0015912.g006
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Glucose transport in isolated soleus muscles was measured using
2-[
3H]2-deoxy-D-glucose as previously described [9]. 2-Deoxyglu-
cose uptake in L6 myocytes was determined as previously
described [11]. In brief, cells were incubated for 8 min in
HEPES-buffered saline containing 10 mM unlabeled 2-deoxyglu-
cose and 10 mM D-2-deoxy-[
3H]glucose (0.5 mCi/ml). The
reaction was terminated by washing three times with ice-cold
0.9% NaCl (w/v). Cell-associated radioactivity was determined by
lysing the cells with 0.05N NaOH, followed by liquid scintillation
counting.
Measurement of Plasma NOx
Nitrite and nitrate (NOx) levels in plasma were measured by
fluorometry. Briefly, blood was collected in tubes containing
EDTA and centrifuged for 10 min at 32006g to obtain plasma,
which was then centrifuged at 50006 g (4uC) overnight in an
UltrafreeH-Microcentrifuge 10,000 NMWL filter unit. Nitrate was
reduced to nitrite using nitrate reductase and the NADPH
regenerating system. The fluorescence was measured using
360 nm excitation and 450 nm emission.
Tyrosine phosphorylation of the insulin receptor and IRS.
Cell or tissue lysates (500 mg of protein) were immunoprecip-
itated with 2 mg of anti-phosphotyrosine (4G10) coupled to protein
A-Sepharose overnight at 4uC. The immune complex was washed
three times in PBS (pH 7.4) containing 1% NP-40 and 2 mmol/l
Na3VO4 , resuspended in Laemmli buffer, and boiled for 5 min.
Proteins were resolved on SDS-PAGE (6% gel) and processed for
western blot analysis.
PI 3-Kinase Activity
Cell or tissue lysates (500 mg) were immunoprecipitated with
2 mg of anti-IRS-1 coupled to protein A-Sepharose overnight at
4uC. PI 3-kinase activity was determined as previously described
[42].
IRS-1 nitrotyrosine measurement
Cell and tissue lysates (500 mg of protein) were immunoprecip-
itated with either 2 mg of IRS-1 antibody or 2 mg of anti-
nitrotyrosine antibody coupled to protein G-Sepharose overnight
at 4uC. The immune complex was washed three times in PBS
(pH 7.4) containing 1% NP-40 and 2 mmol/l Na3VO4, resus-
pended in Laemmli buffer, and boiled for 5 min. Proteins were
resolved on SDS-PAGE (7.5% gel) and processed for western blot
analysis.
Data Analysis
All data are presented as means 6 SEM. The effects of the
treatments were compared by an ANOVA analysis followed by
Fisher’s post hoc test. Differences were considered to be
statistically significant at P,0.05.
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